PURPOSE: Dual-modality PET/MR platforms add a new dimension to patient diagnosis with high resolution, functional, and anatomical imaging. The full potential of this emerging hybrid modality could be realized by using a corresponding dual-modality probe. Here, we report pegylated liposome (LP) formulations, housing a MR T(1) contrast agent (Gd) and the positron-emitting (89)Zr (half-life: 3.27 days), for simultaneous PET and MR tumor imaging capabilities. METHODS: (89)Zr oxophilicity was unexpectedly found advantageous for direct radiolabeling of preformed paramagnetic LPs. LPs were conjugated with octreotide to selectively target neuroendocrine tumors via human somatostatin receptor subtype 2 (SSTr2). (89)Zr-Gd-LPs and octreotide-conjugated homolog were physically, chemically and biologically characterized. RESULTS: (89)Zr-LPs showed reasonable stability over serum proteins and chelator challenges for proof-of-concept in vitro and in vivo investigations. Nuclear and paramagnetic tracking quantified superior SSTr2-recognition of octreotide-LP compared to controls. CONCLUSIONS: This study demonstrated SSTr2-targeting specificity along with direct chelator-free (89)Zr-labeling of LPs and dual PET/MR imaging properties.
PURPOSE: Dual-modality PET/MR platforms add a new dimension to patient diagnosis with high resolution, functional, and anatomical imaging. The full potential of this emerging hybrid modality could be realized by using a corresponding dual-modality probe. Here, we report pegylated liposome (LP) formulations, housing a MR T(1) contrast agent (Gd) and the positron-emitting (89)Zr (half-life: 3.27 days), for simultaneous PET and MR tumor imaging capabilities. METHODS: (89)Zr oxophilicity was unexpectedly found advantageous for direct radiolabeling of preformed paramagnetic LPs. LPs were conjugated with octreotide to selectively target neuroendocrine tumors via humansomatostatin receptor subtype 2 (SSTr2). (89)Zr-Gd-LPs and octreotide-conjugated homolog were physically, chemically and biologically characterized. RESULTS: (89)Zr-LPs showed reasonable stability over serum proteins and chelator challenges for proof-of-concept in vitro and in vivo investigations. Nuclear and paramagnetic tracking quantified superior SSTr2-recognition of octreotide-LP compared to controls. CONCLUSIONS: This study demonstrated SSTr2-targeting specificity along with direct chelator-free (89)Zr-labeling of LPs and dual PET/MR imaging properties.
Authors: E C Dijkers; T H Oude Munnink; J G Kosterink; A H Brouwers; P L Jager; J R de Jong; G A van Dongen; C P Schröder; M N Lub-de Hooge; E G de Vries Journal: Clin Pharmacol Ther Date: 2010-03-31 Impact factor: 6.875
Authors: Hanwen Zhang; Maxim A Moroz; Inna Serganova; Thomas Ku; Ruimin Huang; Jelena Vider; Helmut R Maecke; Steven M Larson; Ronald Blasberg; Peter M Smith-Jones Journal: J Nucl Med Date: 2010-12-13 Impact factor: 10.057
Authors: Jason P Holland; Vadim Divilov; Neil H Bander; Peter M Smith-Jones; Steven M Larson; Jason S Lewis Journal: J Nucl Med Date: 2010-07-21 Impact factor: 10.057
Authors: Vanessa Bellat; Richard Ting; Teresa L Southard; Linda Vahdat; Henrik Molina; Joseph Fernandez; Omer Aras; Tracy Stokol; Benedict Law Journal: Adv Funct Mater Date: 2018-09-14 Impact factor: 18.808
Authors: Carlos Pérez-Medina; Dalya Abdel-Atti; Yachao Zhang; Valerie A Longo; Chrisopher P Irwin; Tina Binderup; Jesús Ruiz-Cabello; Zahi A Fayad; Jason S Lewis; Willem J M Mulder; Thomas Reiner Journal: J Nucl Med Date: 2014-07-24 Impact factor: 10.057
Authors: Jai Woong Seo; Lisa M Mahakian; Sarah Tam; Shengping Qin; Elizabeth S Ingham; Claude F Meares; Katherine W Ferrara Journal: Nucl Med Biol Date: 2014-09-28 Impact factor: 2.408
Authors: Shengping Qin; Brett Z Fite; M Karen J Gagnon; Jai W Seo; Fitz-Roy Curry; Frits Thorsen; Katherine W Ferrara Journal: Ann Biomed Eng Date: 2013-09-10 Impact factor: 3.934
Authors: Chao Wang; Benjamin I Leach; Deanne Lister; Stephen R Adams; Hongyan Xu; Carl Hoh; Patrick McConville; Jing Zhang; Karen Messer; Eric T Ahrens Journal: J Nucl Med Date: 2020-12-04 Impact factor: 10.057